pISSN 3022-6783
eISSN 3022-7712

View

Article View

Korean J Transplant 2023; 37(2): 95-102

Published online June 30, 2023

https://doi.org/10.4285/kjt.23.0020

© The Korean Society for Transplantation

Safely navigating kidney transplantation during the COVID-19 pandemic: the Singapore General Hospital’s experience

Carolyn Shan-Yeu Tien1,2 , Ian Tatt Liew1,2 , Quan Yao Ho1,2 , Sobhana Thangaraju1,2 , Maslinna Binte Abdul Rahman3 , Constance Lee2 , Nicole Chelsi Xin Hui Leah2 , Xia He2 , Li Ting Siew2 , Terence Yi Shern Kee1,2

1Department of Renal Medicine, Singapore General Hospital, Singapore
2Renal Transplant Program, SingHealth Duke-NUS Transplant Centre, Singapore
3Department of Nursing, Singapore General Hospital, Singapore

Correspondence to: Carolyn Shan-Yeu Tien
Department of Renal Medicine, Singapore General Hospital, Level 3, The Academia, 20 College Rd, Singapore 169586, Singapore
E-mail: carolyn.tien.s.y@singhealth.com.sg

Received: April 4, 2023; Revised: June 4, 2023; Accepted: June 22, 2023

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background: The coronavirus disease 2019 (COVID-19) pandemic curtailed transplant activities worldwide, driven by concerns about increased COVID-19-related mortality among kidney transplant recipients (KTRs), infections originating from donors, and decreased availability of surgical and intensive care resources as healthcare resources are reallocated for pandemic response. We examined the outcomes of KTRs at our center before and during the COVID-19 pandemic.
Methods: We conducted a retrospective single-center cohort study examining the characteristics and outcomes of patients undergoing kidney transplantation during two periods: January 1, 2017 to December 31, 2019 (pre-COVID-19 era) and January 1, 2020 to June 30, 2022 (COVID-19 era). We reviewed perioperative and COVID-19 infection-related outcomes in both groups.
Results: A total of 114 transplants were performed during the pre-COVID-19 era, while 74 transplants were conducted during the COVID-19 era. No differences in baseline demographics were observed. Additionally, there were no significant differences in perioperative outcomes, except for a longer cold ischemia time during the COVID-19 era. However, this did not result in an increased incidence of delayed graft function. Among the KTRs infected with COVID-19 during the pandemic era, no severe complications such as pneumonia, acute kidney injury, or death were reported.
Conclusions: With the global transition to an endemic phase of COVID-19, it is imperative to revitalize organ transplant activities. Effective containment workflow, good vaccination uptake, and prompt COVID-19 treatment are essential to ensure that transplants can proceed safely.

Keywords: COVID-19, Organ transplantation, Safety

HIGHLIGHTS
  • Perioperative kidney transplant outcomes during coronavirus disease 2019 (COVID-19) were comparable to the prepandemic era.

  • With appropriate measures, kidney transplantation can safely continue despite the pandemic.

  • Vaccination, recipient-donor screening, and prompt treatment enable optimal outcomes.

Since the first case of coronavirus disease 2019 (COVID-19) was reported in Singapore in January 2020, there have been 2.1 million documented cases of COVID-19 infections in our nation of 6 million people over the past 3 years [1]. During the initial wave of the pandemic, the Ministry of Health issued an advisory to halt nonurgent kidney transplants (KTs). Both deceased donor KTs (DDKTs) and living donor KTs (LDKTs) were suspended due to the uncertainties surrounding the novel virus and the need to reallocate healthcare resources for pandemic response (Fig. 1).

Figure 1. Transplant timeline during the COVID-19 pandemic. COVID-19, coronavirus disease 2019; DDKT, deceased-donor kidney transplantation; LDKT, living-donor kidney transplantation.

Early data indicated that KT recipients (KTRs) experienced a substantial risk of adverse events from COVID-19 infection, including acute kidney injury and mortality rates as high as 23% [2-4]. Both the British and European Renal Associations reported higher mortality in KTRs infected with COVID-19 than in patients on the waiting list [5-7]. Consequently, the initial limitations on transplant activities in Singapore mirrored a global trend to delay transplantation due to concerns about COVID-19-related mortality.

However, this delay in KT conferred the risks of continued dialysis, including the cumulative impact of comorbidities, access-related complications, and posttransplant outcomes [8,9]. A local survey on attitudes toward transplantation revealed that an overwhelming 90.8% of waitlisted patients had a positive response to proceeding with transplantation if organs were made available, even during the pandemic [10]. This sentiment was consistent with that of waitlisted patients in international research [11,12]. Furthermore, the subsequent development of effective monoclonal antibodies, antivirals, and vaccinations has significantly reduced COVID-19 mortality and morbidity [13,14], prompting a reevaluation of the restrictions on KT. As the COVID-19 pandemic progressed and new data became available, nonurgent KT activities in Singapore were cautiously resumed on a limited basis [15]. Nevertheless, this resumption was closely regulated and monitored by public health officials.

Herein, we describe the outcomes of KTs performed at our center from January 1, 2017 to June 30, 2022. KT outcomes during the COVID-19 pandemic were comparable with those in the prepandemic era. This evaluation of KT safety will contribute to guiding the program’s sustainability as we transition into the endemic phase of COVID-19.

This study was approved by the Ethics Review Committee from the SingHealth Centralised Institutional Review Board (No. 2021/2823). Informed consent was waived due to the retrospective nature of this study.

Study Design

We conducted a retrospective single-center cohort study to examine the characteristics and outcomes of patients undergoing KT during two periods: January 1, 2017 to December 31, 2019 (pre-COVID-19 era) and January 1, 2020 to June 30, 2022 (COVID-19 era). Information was collected on baseline characteristics, such as sex, age, waiting time for transplant, and immunological characteristics. Perioperative outcomes and COVID-19 infection-related outcomes in both groups were also reviewed.

Donor Workflow Changes During COVID-19

Our center’s COVID-19 workflow for living and deceased donors is described in Fig. 2. Both DDKT and LDKT donors require negative COVID-19 polymerase chain reaction (PCR) tests and normal chest imaging prior to transplant.

Figure 2. Workflow for living and deceased donor assessment during the COVID-19 pandemic. COVID-19, coronavirus disease 2019; KT, kidney transplantation. a)COVID-19 swabs taken on D-7 and D-1 from KT; b)COVID-19 swabs taken at least 18–24 hours apart; c)Exclusion criteria: (1) any travel history in last 28 days, (2) COVID-19 suspects/cases at time of evaluation.

Recipient Workflow Changes during COVID-19

Our center’s COVID-19 workflow for recipients is described in Fig. 3. All potential transplant recipients require negative COVID-19 PCR tests and normal chest imaging prior to transplant. They should also not have any clinical suspicion for COVID-19 (e.g., respiratory symptoms or fever).

Figure 3. Workflow for recipient assessment during COVID-19. COVID-19, coronavirus disease 2019; KT, kidney transplantation. a)COVID swabs taken on D-7, D-2 and D-1 from KT; b)COVID-19 swab taken before KT; c)Exclusion criteria: (1) any travel history in last 14 days, (2) COVID-19 suspects/cases at time of evaluation.

Immunological Risk

During the initial response to the COVID-19 pandemic, DDKT and LDKT programs were halted (Fig. 1). Subsequently, the DDKT program was first resumed on April 6, 2020 for potential recipients who were considered to have standard immunological risk (i.e., negative flow panel reactive antibodies and negative B and T cell CDC cross-matching with the deceased donor). Similarly, when the LDKT program resumed on July 3, 2020, ABO or human leucocyte antigen-incompatible transplants were not permitted by the Health Ministry. These pandemic measures were implemented to reduce the potential consumption of healthcare resources (such as plasmapheresis in the event of rejection) and to avoid augmented immunosuppression in recipients. This approach was subsequently liberalized with the resumption of our high immunological risk transplants in March 2021.

COVID-19 Preventive Measures

Pretransplant, donors and recipients were advised to self-isolate as much as possible for 2 weeks prior to their admission for LDKT. During this period, we experienced no cancellations or postponements amongst our LDKT pairs due to COVID-19 infection. Posttransplant, they were also advised to minimize congregating in large groups, practice safe distancing, and wear masks. Posttransplant visits were restricted to two named caregivers throughout the admission.

Transplant physicians and allied healthcare staff adhered to hospital infection-control policies. Mandatory twice-daily temperature checks with electronic logs were implemented from February 8, 2020 to March 11, 2021 before these measures were discontinued for vaccinated healthcare workers. Mandatory twice-weekly COVID-19 PCR testing was also implemented from May 8, 2021 to March 21, 2022. Strict safe distancing and mandatory mask wearing have been observed in the transplant unit since the beginning of the pandemic and continue to be enforced. Any staff member diagnosed with COVID-19 was required to take medical leave and provide a negative COVID-19 PCR test result before returning to work.

Vaccination Uptake

With the rollout of mass vaccinations, donors and recipients were advised to be fully vaccinated and boosted against COVID-19 pretransplant. The vaccination schedule adhered to national directives, which consisted of an enhanced primary series with three doses and one booster for KTRs [16]. For KTRs who had not yet started or completed their vaccination, this was done 6 months posttransplant. We achieved a vaccination rate of more than 90% amongst our transplant recipients despite vaccine hesitancy [17]. Nationally, 93% of the Singaporean population has completed the full vaccination regimen and 80% have received a booster [1].

COVID-19 Treatment

KTRs who contracted COVID-19 infection were triaged virtually via video consultation with transplant physicians. Depending on their clinical status, they were either enrolled in a remotely monitored home recovery program or admitted for inpatient care at our transplant center [18]. However, patients who were critically ill were taken to their nearest hospitals, which may not have had transplant services. In those cases, nephrologists usually consulted the primary transplant physician for guidance if needed.

For patients on triple immunosuppression, the anti-metabolite (azathioprine, mycophenolate mofetil [MMF]) was reduced or suspended for KTRs who had moderate severity of COVID-19 infection, such as radiological evidence of pneumonia, or had lymphopenia. Additional antivirals (remdesivir) or monoclonal antibodies (tixagevimab/cilgavimab, casirivimab/imdevimab, sotrovimab) were administered for KTRs based on the severity of their COVID-19 infection, symptom duration, vaccination status, and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) receptor binding domain levels.

Statistical Analyses

Continuous variables are presented as means and standard deviations if normally distributed, while non-normally distributed data are presented as median and interquartile range. Categorical variables are reported as frequencies and percentages. The chi-square test and the independent-sample t-test were used to compare characteristics between KTRs in the pre-COVID-19 era and those in the COVID-19 era. A two-tailed P<0.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS ver. 25.0 (IBM Corp.).

Baseline Demographics

In total, 114 transplants were done during the pre-COVID-19 era, while 74 transplants were performed during the COVID-19 era. Patients’ baseline demographics are shown in Table 1. No statistically significant differences were observed, except that deceased donor recipients during the COVID-19 era had a shorter waiting time (3.2 years) than before COVID-19 (5.3 years).

Table 1. Demographics and transplant characteristics

VariablePre-COVID-19 (n=114)COVID-19 (n=74)P-value
Age (yr)47.7±10.547.5±10.90.9
Male sex58 (51)45 (61)<0.05
Ethnicity0.29
Chinese79 (69)55 (74)
Malay19 (17)9 (12)
Indian6 (5)6 (8)
Other10 (9)4 (5)
Cause of renal failure0.38
Glomerulonephritis74 (65)46 (62)
Diabetic kidney disease19 (17)11 (15)
Polycystic kidney disease11 (10)4 (5)
Other10 (9)13 (18)
Diabetes mellitus18 (16)18 (24)0.15
Coronary artery disease22 (19)22 (30)0.09
Renal replacement therapy0.12
None (preemptive)5 (4)9 (12)
Hemodialysis86 (75)49 (66)
Peritoneal dialysis23 (20)16 (22)
Waiting time for transplant (yr)5.3±4.93.2±3.8<0.05
Type of donor<0.05
Living donor51 (45)49 (66)
Standard-criteria deceased donor42 (37)17 (23)
Expanded-criteria deceased donor17 (15)3 (4)
Donation after cardiac death4 (4)5 (7)
Preemptive transplant14 (12)12 (16)0.4
High immunological risk transplant0.38
ABO-incompatible7 (6)8 (11)
Positive cross-match12 (10)5 (7)
Preformed DSA32 (28)25 (34)0.4
Antibody induction<0.05
Basiliximab103 (90)51 (69)
Thymoglobulin11 (10)23 (31)
Immunosuppression regimen<0.05
CsA + PRED + MPA3 (3)16 (22)
TAC + PRED + MPA111 (97)57 (77)
CsA + PRED + MPA + EVL01 (1)

Values are presented as mean±standard deviation or number (%).

COVID-19, coronavirus disease 2019; DSA, donor-specific antibodies; CsA, cyclosporin A; PRED, prednisone; MPA, mycophenolic acid; TAC, tacrolimus; EVL, everolimus.



Transplant Characteristics

During the COVID-19 era, LDKTs were more prevalent than during the pre-COVID-19 era (66% vs. 45%, P<0.05). The majority of transplants performed in both periods were in patients at standard immunological risk (82% in the COVID-19 era vs. 84% in the pre-COVID-19 era, P=0.38), and KTRs primarily received basiliximab for induction therapy (69% in the COVID-19 era vs. 90% in the pre-COVID-19 era, P<0.05). However, there was a higher overall percentage of KTRs receiving thymoglobulin (antithymocyte globulin [ATG]) for induction in the COVID-19 era than in the pre-COVID-19 era (31% vs. 10%, P<0.05). This increase was due to a change in our induction protocol for intermediate-risk transplants (positive donor-specific antibodies with negative cross-matching), which shifted from basiliximab to ATG. In the pre-COVID-19 era, 97% of our KTRs were placed on a tacrolimus-based regimen, while only 77% were on this regimen during the COVID-19 era. This change was also due to a shift in our center’s immunosuppression protocol, which transitioned to a cyclosporine-based regimen for KTRs at standard immunological risk. This decision was based on in-center data that showed increased infective complications (e.g., BK virus) among KTRs on tacrolimus-based regimens.

Perioperative Outcomes

There were no significant differences between the two groups in terms of surgical complications, postoperative infectious complications, length of hospital stay, or 6-month graft and patient survival (Table 2). We observed a longer cold ischemia time in the COVID-19 era than in the pre-COVID-19 era (6.7 vs. 4.0 hours, P<0.05). However, this increase in cold ischemia time did not result in a higher incidence of delayed graft function (34% vs. 23%, P=0.10) or biopsy-proven rejection (20% vs. 5%, P=0.01).

Table 2. Perioperative outcomes

VariablePre-COVID-19 (n=114)COVID-19 (n=74)P-value
Cold ischemia time (hr)4.0±4.76.7±5.8<0.05
Delayed graft function39 (34)17 (23)0.10
Postoperative admission to intensive care unit2 (2)2 (3)0.66
Return to operating theater2 (2)2 (3)0.66
Biopsy proven rejection23 (20)4 (5)0.01
Surgical complication9 (8)9 (12)0.33
Postoperative infective complication24 (21)13 (18)0.56
Postoperative cardiovascular complication5 (4)5 (7)0.48
Discharge estimated glomerular filtration rate (mL/min)57±2858±250.76
Length of hospital stay (day)17±1018±80.36
Readmission within 30 days of surgery38 (33)29 (39)0.53
6-Month graft survival113 (99)74 (100)0.42
6-Month patient survival113 (99)74 (100)0.42

Values are presented as mean±standard deviation or number (%).

COVID-19, coronavirus disease 2019.



COVID-19-Related Outcomes

The vaccination rates in both our pre-COVID-19 and COVID-19 era groups were high with 89% and 95% of the recipients, respectively, having received at least three doses (Table 3) and there were no cases of donor-transmitted COVID-19 infection.

Table 3. COVID-19–related demographics

DemographicsPre-COVID-19
(n=114)
COVID-19
(n=74)
P-value
At least three COVID-19 vaccine doses101 (89)70 (95)0.19
Pretransplant COVID-19NA4 (5)NA
Posttransplant COVID-1948 (42)26 (35)0.34
Donor-transmitted COVID-19NA0NA

Values are presented as number (%).

COVID-19, coronavirus disease 2019; NA, not applicable.



Among the KTRs who contracted COVID-19, no significant differences in outcomes were observed compared to patients in the pre-COVID-19 era (Table 4). KTRs in the COVID-19 era who did contract the virus did not experience severe complications, such as pneumonia, acute kidney injury, intensive care unit admissions, or death, even though their transplants were more recent at the time of COVID-19 infection.

Table 4. COVID-19 infection outcomes

COVID-19 infected patientsPre-COVID-19 (n=48)COVID-19 (n=26)P-value
SARS-CoV-2 IgG >1,000 AU/mL15 (31)8 (31)0.97
ISARIC 4-C score4.8±2.64.2±2.30.36
Pneumonia8 (17)00.08
Oxygen therapy3 (6)1 (4)0.83
Admission to intensive care unit1 (2)00.48
Acute kidney injury3 (6)00.39
Death1 (2)00.69

Values are presented as number (%) or mean±standard deviation.

COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; IgG, immunoglobulin G.


Data on the outcomes of KTs performed in Asia during the COVID-19 era are limited to single-center case studies and one multi-center study from India [19,20]. Therefore, it was crucial for us to examine our own center’s data to determine whether the outcomes of KTs conducted during this period were consistent with those reported in the literature. During the COVID-19 era, KT outcomes were found to be comparable to those performed before the pandemic. Although fewer transplants were conducted, our data indicate that the perioperative outcomes of KTs in the COVID-19 era were not inferior to those in the pre-COVID era.

Despite the longer cold ischemia time resulting from the extended assessment period for DDKT recipients due to the need for COVID-19 PCR processing, there was no increase in rates of delayed graft function. Several factors may contribute to this observation. First, there was a decreased incidence of biopsy-proven rejection, which was not unexpected since only standard immunological risk transplants were allowed during the initial pandemic response. Second, more LDKTs than DDKTs were performed during the COVID-19 period, and LDKTs generally have lower rates of delayed graft function. Finally, fewer extended-criteria donor kidneys were transplanted during this time.

The reduction in the proportion of DDKTs can be attributed to strict infection control measures, which likely excluded a significant number of potential deceased donors considered at risk for transmission. Additionally, our DDKT recipients during the COVID-19 era experienced shorter waiting times for transplantation, likely due to the exclusion of sensitized patients on the waitlist, who were deemed to be at a higher immunological risk.

During the COVID-19 era, over 30% of our KTRs developed COVID-19 infections; however, none experienced severe complications or mortality. This outcome was likely due to high vaccination rates and prompt COVID-19 treatment, with the majority of our patients receiving either antiviral medications or monoclonal antibodies. Furthermore, we observed the emergence of SARS-CoV-2 variants that were more infectious but had lower mortality rates. In Singapore, the Delta B16172 strain became dominant in April 2021, followed by the Omicron BA.1 strain in January 2022. This led to a resurgence of cases. In July 2022, the Omicron BA.4/5 variant drove a surge in COVID-19 cases, and from September 2022 onwards, the Omicron XBB variant became dominant. Similar observations were reported in the United States and Europe, where they also experienced a higher number of COVID-19 cases amongst transplant recipients during the Omicron surge. However, there was no increase in mortality or hospitalization rates [13,14].

Our study findings provide reassurance that, with appropriate precautions, safe renal transplantation can be carried out for patients during the ongoing pandemic. It is also essential to encourage recipients to receive COVID-19 vaccinations and stay current with booster shots against emerging variants, as vaccines have been demonstrated to lessen complications and decrease mortality risk in the event of a COVID-19 infection [17,21,22].

Our study had some limitations. First, this was a single-center study; however, our research was conducted at the largest quaternary-level KT center in Singapore, which provides care to the majority of the nation’s KTRs (approximately 867 recipients). Second, there may be limitations to the generalizability of our findings. Singapore has a high vaccination rate among the general population, with vaccination universally encouraged. COVID-19-related care in government institutions, including monoclonal and antiviral therapy as well as hospitalization, is heavily subsidized by the government, resulting in limited out-of-pocket costs for patients. Furthermore, the robust communications and healthcare infrastructure enable remotely monitored home recovery programs. However, these resources may not be available to all healthcare institutions.

As COVID-19 transitions from a pandemic to an endemic disease, it is crucial for countries to recommence transplant activities. We are confident that through a meticulous workflow involving careful screening, high vaccination uptake, and swift treatment for COVID-19, we can safely continue performing transplants for our patients.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Author Contributions

Conceptualization: TYSK. Data curation: all authors. Formal analysis: TYSK . Methodology: TYSK. Project administration: all authors. Writing–original draft: CSYT, ITL. Writing–review & editing: all authors. All authors read and approved the final manuscript.

Additional Contributions

We thank Dr. Jasmine Chung (Singapore General Hospital, Department of Infectious Diseases), Dr. Michelle Tan (Singapore General Hospital, Family Medicine and Continuing Care) for providing us with support and advice for management of our patients with COVID-19 in the hospital and at the home recovery program. We would also like to thank the rest of our dedicated team of transplant coordinators: Yong Jinhua, Natalie Kwan, Eleanor Ng, Tan Jiaqin, Lee Chin Yee, Sharel Ong, Judy Tan, Joey Kay and Jenny Leong, without whom the program would not have succeeded. Lastly, we would also like to thank our inpatient team of nurses and allied professionals who have worked tirelessly throughout the COVID-19 pandemic and beyond.

  1. Ministry of Health, Singapore (MOH). COVID-19 statistics [Internet]. MOH; 2023 [cited 2022 Dec 1].
    Available from: https://www.moh.gov.sg.
  2. Kee T, Jeong JC, Ur-Rashid H, Begum NA, Arakama MH, Danguilan R, et al. Clinical characteristics, outcomes, and management of COVID-19 in kidney transplant recipients across Asia: an ASTREGO report. Korean J Transplant 2021;35:218-29.
    Pubmed KoreaMed CrossRef
  3. Kremer D, Pieters TT, Verhaar MC, Berger SP, Bakker SJ, van Zuilen AD, et al. A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: lessons to be learned. Am Transplant 2021;21:3936-45.
    Pubmed KoreaMed CrossRef
  4. Ho QY, Sultana R, Lee TL, Thangaraju S, Kee T, Htay H. Coronavirus disease 2019 in kidney transplant recipients: a systematic review and meta-analysis. Singapore Med J 2021 Oct 24. [Epub]. https://doi.org/10.11622/smedj.2021171.
    CrossRef
  5. Mohamed IH, Chowdary PB, Shetty S, Sammartino C, Sivaprakasam R, Lindsey B, et al. Outcomes of renal transplant recipients with SARS-CoV-2 infection in the eye of the storm: a comparative study with waitlisted patients. Transplantation 2021;105:115-20.
    Pubmed CrossRef
  6. Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez JE, Garneata L, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int 2020;98:1540-8.
    Pubmed KoreaMed CrossRef
  7. Goffin E, Candellier A, Vart P, Noordzij M, Arnol M, Covic A, et al. COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. Nephrol Dial Transplant 2021;36:2094-105.
    Pubmed KoreaMed CrossRef
  8. Meier-Kriesche HU, Port FK, Ojo AO, Rudich SM, Hanson JA, Cibrik DM, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000;58:1311-7.
    Pubmed CrossRef
  9. Ho QY, Chung SJ, Gan VH, Ng LG, Tan BH, Kee TY. High-immunological risk living donor renal transplant during the COVID-19 outbreak: uncertainties and ethical dilemmas. Am J Transplant 2020;20:1949-51.
    Pubmed KoreaMed CrossRef
  10. Tan EK, Koh YX, Kee T, Juhari JB, Tan TE, Sim DK, et al. Waitlisted transplant candidates' attitudes and concerns toward transplantation during COVID-19. Ann Transplant 2020;25:e926992.
    Pubmed KoreaMed CrossRef
  11. Couzi L, Manook M, Caillard S, Épailly É, Barrou B, Anglicheau D, et al. Impact of Covid-19 on kidney transplant and waiting list patients: lessons from the first wave of the pandemic. Nephrol Ther 2021;17:245-51.
    Pubmed KoreaMed CrossRef
  12. Thind AK, Beckwith H, Dattani R, Dhutia A, Gleeson S, Martin P, et al. Resuming deceased donor kidney transplantation in the COVID-19 era: what do patients want? Transplant Direct 2021;7:e678.
    Pubmed KoreaMed CrossRef
  13. Heldman MR, Kates OS, Safa K, Kotton CN, Georgia SJ, Steinbrink JM, et al. Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic. Am J Transplant 2022;22:279-88.
    Pubmed KoreaMed CrossRef
  14. Cochran W, Shah P, Barker L, Langlee J, Freed K, Boyer L, et al. COVID-19 clinical outcomes in solid organ transplant recipients during the Omicron surge. Transplantation 2022;106:e346-7.
    Pubmed KoreaMed CrossRef
  15. Ministry of Health, Singapore. Advisory on health measures for organ and tissue recovery and transplantation: COVID-19 Dorscon Orange. Ministry of Health, Singapore; 2020.
  16. Ministry of Health, Singapore. Update to booster vaccine recommendations. Ministry of Health, Singapore; 2022.
  17. Liew IT, Kadir HA, Thangaraju S, Ho QY, Ng E, Foo F, et al. COVID-19 vaccine acceptance among kidney transplant recipients in Singapore. Singapore Med J 2023 Apr 26 [Epub]. https://doi.org/10.4103/singaporemedj.SMJ-2021-332
    Pubmed CrossRef
  18. Liew IT, Tan WJ, Ho QY, Thangaraju S, Yong JH, Ng E, et al. COVID-19 infected kidney transplant patients outpatient management-a single-center experience with a hospital-at-home program. Transplantation 2022;106:e525-7.
    Pubmed KoreaMed CrossRef
  19. Lee J, Kim EJ, Ihn K, Lee JG, Joo DJ, Kim MS, et al. The feasibility of organ transplantation during the COVID-19 outbreak: experiences from South Korea. Korean J Transplant 2020;34:257-64.
    Pubmed KoreaMed CrossRef
  20. Jha PK, Yadav DK, Siddini V, Bansal SB, Sharma R, Anandh U, et al. A retrospective multi-center experience of renal transplants from India during COVID-19 pandemic. Clin Transplant 2021;35:e14423.
    KoreaMed CrossRef
  21. Tsapepas D, Paget K, Mohan S, Cohen DJ, Husain SA. Clinically significant COVID-19 following SARS-CoV-2 vaccination in kidney transplant recipients. Am J Kidney Dis 2021;78:314-7.
    Pubmed KoreaMed CrossRef
  22. Ravanan R, Mumford L, Ushiro-Lumb I, Callaghan C, Pettigrew G, Thorburn D, et al. Two doses of SARS-CoV-2 vaccines reduce risk of death due to COVID-19 in solid organ transplant recipients: preliminary outcomes from a UK registry linkage analysis. Transplantation 2021;105:e263-4.
    Pubmed KoreaMed CrossRef